Hepatitis B Virus Reactivation Associated With Therapeutic Interventions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Young | - |
dc.contributor.author | Jeong, Soung Won | - |
dc.contributor.author | Jang, Jae Young | - |
dc.date.accessioned | 2022-02-07T01:40:49Z | - |
dc.date.available | 2022-02-07T01:40:49Z | - |
dc.date.issued | 2022-01-14 | - |
dc.identifier.issn | 2296-858X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20336 | - |
dc.description.abstract | Hepatitis B virus (HBV) reactivation associated with various therapeutic interventions is an important cause of morbidity and mortality in patients with current or resolved HBV infection. Because no curative treatment for HBV infection is yet available, there are many individuals at risk for HBV reactivation in the general population. Populations at risk for HBV reactivation include patients who are currently infected with HBV or who have been exposed to HBV in the past. HBV reactivation and its potential consequences is a concern when these populations are exposed to anti-cancer chemotherapy, immunosuppressive or immunomodulatory therapies for the management of various malignancies, rheumatologic diseases, inflammatory bowel disease, or solid-organ or hematologic stem cell transplantation. Accordingly, it has become important to understand the basics of HBV reactivation and the mechanisms by which certain therapies are more susceptible to HBV reactivation. This review aims to raise the awareness of HBV reactivation and to understand the mechanisms and the risks of HBV reactivation in various clinical settings. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | Hepatitis B Virus Reactivation Associated With Therapeutic Interventions | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3389/fmed.2021.770124 | - |
dc.identifier.scopusid | 2-s2.0-85123923557 | - |
dc.identifier.wosid | 000748150600001 | - |
dc.identifier.bibliographicCitation | Frontiers in Medicine, v.8, no.0, pp 1 - 9 | - |
dc.citation.title | Frontiers in Medicine | - |
dc.citation.volume | 8 | - |
dc.citation.number | 0 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | DOSE METHOTREXATE THERAPY | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | ACTING ANTIVIRAL THERAPY | - |
dc.subject.keywordPlus | RESOLVED HBV INFECTION | - |
dc.subject.keywordPlus | OCCULT VIRAL CARRIERS | - |
dc.subject.keywordPlus | SURFACE-ANTIGEN | - |
dc.subject.keywordPlus | CANCER-PATIENTS | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | CYTOTOXIC CHEMOTHERAPY | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordAuthor | hepatitis B | - |
dc.subject.keywordAuthor | reactivation | - |
dc.subject.keywordAuthor | immunosuppressant | - |
dc.subject.keywordAuthor | molecular target agents | - |
dc.subject.keywordAuthor | direct-acting antivirals | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.